ImpactRx Broadens Innovative Research Capability Through Acquisition of Paragon Research...

ImpactRx Broadens Innovative Research Capability Through Acquisition of
Paragon Research and Consulting
Combined company to provide an unprecedented level of insight into the US
pharmaceutical market

MOUNT LAUREL, N.J., Jan. 15 /PRNewswire/ -- ImpactRx, Inc., the pioneering
force in measuring the impact of pharmaceutical promotion on physicians'
prescribing behavior, announced today that it has acquired Paragon Research &
Consulting, Inc. of West Chester, PA. Paragon will now apply its innovative
analytical and custom research capabilities to ImpactRx's proprietary data to
provide the most timely, accurate and sensitive evaluation of the
pharmaceutical market and of individual company and brand performance.
"ImpactRx's data combined with Paragon's analytics and research expertise
will provide our clients with unparalleled visibility into the pharmaceutical
marketplace," stated Richard Altus, CEO and President of ImpactRx. "The
synergies we will create across our organizations will allow us to further
leverage ImpactRx's unique data assets to deliver an unprecedented level of
market insight."
"ImpactRx's unique research and business model has been validated as we
embark on our eighth year of operation," Altus continued. "After several
solid years of revenue growth coupled with increasing profitability, we are
now generating sufficient cash flow to acquire complementary companies that
extend our value proposition to pharmaceutical sales and marketing management.
The Paragon acquisition and the recent expansion of our physician information
networks are two important examples of our commitment to extending our
capabilities to respond to the emerging information and analytical needs of
our customers."
Paragon, founded in 1991 by Dr. Robert Zelnio, is a full service
pharmaceutical market research and consulting firm committed to helping
clients gain competitive advantage by providing customized solutions to
complex business problems. "For our part," Zelnio noted, "we think our
association with ImpactRx will begin a whole new era of innovation. We are
excited to join forces with ImpactRx. Their data offers a view into market
activity that we can use to benefit our clients. It goes well beyond that
provided by traditional dispensed prescriptions. We're brimming over with
ideas for new methods and studies we can develop to support our clients'
marketing research needs and are equally enthusiastic about applying the
research and analytical skills of Paragon's team to ImpactRx's impressive
database. Through our combined expertise we will be able to provide all
clients with a more complete and more actionable understanding of their
marketing and sales challenges."
About ImpactRx
Founded in October 2000, ImpactRx' physician networks are the source of an
unprecedented intelligence capability for tracking the promotional initiatives
of the pharmaceutical industry and for measuring their impact on physician
prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private
company with investment financing provided by Mediphase Venture Partners
(www.mediphaseventure.com), Oxford Bioscience Partners (www.oxbio.com), Merck
Capital Ventures (www.merckcapitalventures.com) and 3i Group (www.3i.com).
CONTACT:
John Kain
Vice President, Marketing
ImpactRx, Inc.
856-273-0221, ext. 141
jkain@impactrx.com

SOURCE ImpactRx, Inc.

John Kain, Vice President, Marketing of ImpactRx, Inc., +1-856-273-0221, ext.
141, jkain@impactrx.com